Acetylcholinesterase Inhibitor in Anorexia Nervosa: Multicenter, Double-Blind, Placebo-Controlled Trial

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorCentre Hospitalier St Anne

About this trial

The goal of this clinical trial is to learn if the daily take of donepezil can treat adult patient suffering from anorexia nervosa. The main question it aims to answer is : do daily donepezil intake permit weight gain and reduction of food restriction rituals ? The treatment is a capsule comprising a drug limiting the degradation of a neurotransmitter called acetylcholine. This treatment has long been used to treat certain cognitive disorders. Researchers will compare two drug dosage and a look-alike capsule that contains no drug to see if the dose has an impact on the effect. Participants will take one capsule per day for three months will have regular hospital visits for cognitive and metabolic tests.

Eligibility criteria

Qualifiers

Female

Presence of the 3 DSM-V criteria for Anorexia Nervosa

Restrictive subtype of Anorexia Nervosa according to DSM-5

Body Mass Index between 15 and 18.5 kg/m²

Disqualifiers

Presence of one or more somatic criteria for hospitalization according to french HAS 2010 guidelines

Past diagnosis of anorexia nervosa with binge-eating/purging type

Past diagnosis of bulimia nervosa

Past diagnosis of binge-eating disorder

Trial design

Treatments tested in this trial

  • Donepezil 2.5 mg
  • Donepezil 5 mg
  • Placebo Comparator

Treatment groups

147 Participants
are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Centre Hospitalier St Anne

Lead sponsor

Université Paris Cité

Collaborator

Institut National de la Santé Et de la Recherche Médicale, France

Collaborator